Michael D. Laufert
Keine laufenden Positionen mehr
Profil
Mr. Laufert was previously employed as a Principal by GCP Fund III Corp., a Principal by Guilford Pharmaceuticals, Inc., and a Principal by Pfizer Inc.
Mr. Laufert received his undergraduate degree from Mount St. Mary's College, a graduate degree from Georgetown University, and an MBA from Johns Hopkins University.
Ehemalige bekannte Positionen von Michael D. Laufert
| Unternehmen | Position | Ende |
|---|---|---|
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Corporate Officer/Principal | - |
| GCP Fund III Corp. | Corporate Officer/Principal | - |
| PFIZER, INC. | Corporate Officer/Principal | - |
Ausbildung von Michael D. Laufert
| The Johns Hopkins University | Masters Business Admin |
| Mount Saint Mary's University | Undergraduate Degree |
| Georgetown University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
| GCP Fund III Corp. |
